Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Together with The University of Texas Southwestern Medical Center, Co. has a portfolio of gene therapy product candidates. Co.'s portfolio of gene therapy candidates targets neurological indications across three therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Co. owns worldwide rights to a clinical-stage intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy. The TSHA average annual return since 2020 is shown above.
The Average Annual Return on the TSHA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TSHA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TSHA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|